The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects
Abstract
BACKGROUND: In preclinical studies, lysolipid-based temperature-sensitive liposomes (LTSLs) containing chemotherapy drugs administered in combination with local hyperthermia have been found to increase tumor drug concentrations and improve antitumor efficacy of the drugs. We used a novel magnetic resonance imaging (MRI) method to measure the temporal and spatial patterns of drug delivery in a rat fibrosarcoma model during treatment with LTSLs containing doxorubicin and an MRI contrast agent (manganese) (Dox/Mn-LTSLs) administered at different times with respect to hyperthermia. METHODS: Rats bearing 10- to 12-mm fibrosarcomas (n = 6-7 per group) were treated with Dox/Mn-LTSLs (at a dose of 5 mg doxorubicin/kg body weight) before and/or during 60 minutes of local tumor hyperthermia administered via a catheter inserted at the center of the tumor. Drug distribution was monitored continuously via MRI. Magnetic resonance changes were used to calculate intratumoral doxorubicin concentrations throughout treatment. Tumors were monitored until they reached five times their volume on the day of treatment or 60 days. Doxorubicin concentrations and times for tumors to reach five times their volume on the day of treatment were analyzed using the Kruskal-Wallis test and the Kaplan-Meier product-limit method, respectively. All statistical tests were two-sided. RESULTS: Administration of Dox/Mn-LTSLs before, during, and both before and during hyperthermia yielded central, peripheral, and uniform drug distributions, respectively. Doxorubicin accumulated more quickly and reached higher concentrations in the tumor when Dox/Mn-LTSLs were administered during hyperthermia than when administered before hyperthermia (rate: 9.8 versus 1.8 microg/min, difference = 8.0 microg/min, 95% confidence interval [CI] = 6.8 to 12.8 microg/min, P = .003; concentration: 15.1 versus 8.0 ng/mg, difference = 7.1 ng/mg, 95% CI = 3.6 to 10.6 ng/mg, P = .028). LTSL administered during hyperthermia also yielded the greatest antitumor effect, with a median time for tumors to reach five times their volume on the day of treatment of 34 days (95% CI = 30 days to infinity) compared with 18.5 days (95% CI = 16 to 23 days) for LTSL before hyperthermia and 22.5 days (95% CI = 15 to 25 days) for LTSL before and during hyperthermia. CONCLUSIONS: In this rat fibrosarcoma model, LTSLs were most effective when delivered during hyperthermia, which resulted in a peripheral drug distribution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE COLORIMETRIC DETERMINATION OF PHOSPHORUS
Fiske, C. H., & Subbarow, Y. (1925) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)84756-1 · Cited by 18,997
Phosphorus Assay in Column Chromatography
Bartlett, G. R. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70226-3 · Cited by 12,801
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Needham, D., Anyarambhatla, G., Kong, G., & Dewhirst, M. W. (2000) · PubMed · Cited by 746
Self-citationHyperthermia enables tumor-specific nanoparticle delivery: effect of particle size.
Kong, G., Braun, R. D., & Dewhirst, M. W. (2000) · PubMed · Cited by 633
Self-citationKong, G., Anyarambhatla, G., Petros, W. P., Braun, R. D., Colvin, O. M., Needham, D., & Dewhirst, M. W. (2000) · PubMed · Cited by 505
Self-citationHahn, G. M., Braun, J., & Har-Kedar, I. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.3.937 · Cited by 480
Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature.
Kong, G., Braun, R. D., & Dewhirst, M. W. (2001) · PubMed · Cited by 442
Self-citationGabizón, A., Price, D. C., Huberty, J. P., Bresalier, R. S., & Papahadjopoulos, D. (1990) · PubMed · Cited by 249
Mills, J. K., & Needham, D. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.08.007 · Cited by 236
Saito, R., Bringas, J. R., McKnight, T. R., Wendland, M. F., Mamot, C., Drummond, D. C., Kirpotin, D. B., Park, J. W., Berger, M. S., & Bankiewicz, K. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3631 · Cited by 231
Anyarambhatla, G. R., & Needham, D. (1999) · Journal of Liposome Research · doi:10.3109/08982109909035549 · Cited by 199
Viglianti, B. L., Abraham, S. A., Michelich, C. R., Yarmolenko, P. S., MacFall, J. R., Bally, M. B., & Dewhirst, M. W. (2004) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20074 · Cited by 192
Self-citationKoukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., & Helidonis, E. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3512 · Cited by 191
Formation of transition metal–doxorubicin complexes inside liposomes
Abraham, S. A., Edwards, K., Karlsson, G., MacIntosh, S., Mayer, L. D., McKenzie, C., & Bally, M. B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00507-2 · Cited by 168
Self-citationSaito, R., Krauze, M. T., Bringas, J. R., Noble, C. O., McKnight, T. R., Jackson, P., Wendland, M. F., Mamot, C., Drummond, D. C., Kirpotin, D. B., et al. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.016 · Cited by 150
Gabizón, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., Fromer, I. R., Peretz, T., Sulkes, A., & Barenholz, Y. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.476 · Cited by 144
Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome
Chen, Q., Tong, S., Dewhirst, M. W., & Yuan, F. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1311.3.10 · Cited by 133
Self-citationChemodosimetry of in vivo tumor liposomal drug concentration using MRI
Viglianti, B. L., Ponce, A. M., Michelich, C. R., Yu, D., Abraham, S. A., Sanders, L. L., Yarmolenko, P., Schroeder, T., MacFall, J. R., Barboriak, D. P., et al. (2006) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21032 · Cited by 130
Self-citationGløgård, C., Stensrud, G., Hovland, R., Fossheim, S. L., & Klaveness, J. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00935-8 · Cited by 101
Krauze, M. T., McKnight, T. R., Yamashita, Y., Bringas, J., Noble, C. O., Saito, R., Geletneky, K., Forsayeth, J., Berger, M. S., Jackson, P., et al. (2005) · Brain Research Protocols · doi:10.1016/j.brainresprot.2005.08.003 · Cited by 94
Cope, D. A., Dewhirst, M. W., Friedman, H. S., Bigner, D. D., & Zalutsky, M. R. (1990) · PubMed · Cited by 78
Self-citationEffects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen
Krauze, M. T., Saito, R., Noble, C. O., Bringas, J. R., Forsayeth, J., McKnight, T. R., Park, J. Y., & Bankiewicz, K. S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.009 · Cited by 75
Heat-activated Liposomal MR Contrast Agent: Initial in Vivo Results in Rabbit Liver and Kidney
McDannold, N. J., Fossheim, S. L., Rasmussen, H., Martin, H. R., Vykhodtseva, N. I., & Hynynen, K. (2004) · Radiology · doi:10.1148/radiol.2303021713 · Cited by 73
Biomedical magnetic resonance imaging : principles, methodology, and applications
Wehrli, F. W., Shaw, D., & Kneeland, J. B. (1988) · Medical Entomology and Zoology · Cited by 67
The use of scintigraphic imaging as a tool in the development of liposome formulations
Goins, B., & Phillips, W. T. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00014-x · Cited by 52
Løkling, K., Fossheim, S. L., Klaveness, J., & Skurtveit, R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.04.015 · Cited by 47
Principles of Dose, Schedule, and Combination Therapy
Hait, W. N., & Eder, J. P. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm055.pub2 · Cited by 32
Automated feedback control of body temperature for small animal studies with MR microscopy
Qiu, H. H., Cofer, G. P., Hedlund, L. W., & Johnson, G. A. (1997) · IEEE Transactions on Biomedical Engineering · doi:10.1109/10.641338 · Cited by 31
Cited by
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“rabbits [199,200] and it has shown clear benefits as compared to the administration of free drugs or standard liposomes in multiple different tumor models, including cervical, lung and breast cancer [201].”
BackgroundRethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Self-citationLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Metadata
- Authors
- Ponce, A. M., Viglianti, B. L., Yu, D., Yarmolenko, P. S., Michelich, C. R., Woo, J., Bally, M. B., & Dewhirst, M. W.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-03
- Volume
- 99
- Issue
- 1
- Pages
- 53-63
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2111220039
- Cited by
- 273
- References
- 31
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.